$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

$mrsn Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000162828023027989 Filed on August 08, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$7.698M	$10.65M
YoY Change	38.13%	148.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.89M	$18.19M
YoY Change	-11.55%	22.86%
% of Gross Profit
Research & Development	$30.53M	$48.97M
YoY Change	-39.71%	18.77%
% of Gross Profit
Depreciation & Amortization	$430.0K	$324.0K
YoY Change	101.88%	42.73%
% of Gross Profit
Operating Expenses	$51.64M	$67.16M
YoY Change	-20.81%	19.85%
Operating Profit
YoY Change
Interest Expense	$1.017M	$1.025M
YoY Change	15.57%	34.87%
% of Operating Profit
Other Income/Expense, Net	$2.285M	$2.194M
YoY Change	-1428.49%	-567.8%
Pretax Income	-$41.66M	-$54.31M
YoY Change	-30.35%	4.0%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$41.70M	-$54.30M
YoY Change	-30.27%	4.02%
Net Earnings / Revenue	-541.7%	-509.67%
Basic Earnings Per Share	-$0.35	-$0.47
Diluted Earnings Per Share	-$0.35	-$0.47
COMMON SHARES
Basic Shares Outstanding	120.5M shares	114.4M shares
Diluted Shares Outstanding	120.5M shares	115.6M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$241.0M	$286.6M
YoY Change	-16.93%	27.3%
Cash & Equivalents	$186.3M	$128.7M
Short-Term Investments	$54.70M	$157.9M
Other Short-Term Assets	$8.800M	$10.50M
YoY Change	-11.21%	-12.15%
Inventory
Prepaid Expenses
Receivables	$0.00	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$249.7M	$297.1M
YoY Change	-16.76%	25.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.70M	$13.40M
YoY Change	-10.54%	-7.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$478.0K	$517.0K
YoY Change	-22.4%	-28.59%
Total Long-Term Assets	$13.17M	$13.91M
YoY Change	-11.12%	-8.9%
TOTAL ASSETS
Total Short-Term Assets	$249.7M	$297.1M
Total Long-Term Assets	$13.17M	$13.91M
Total Assets	$262.9M	$311.0M
YoY Change	-16.5%	23.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.95M	$16.92M
YoY Change	-5.72%	107.38%
Accrued Expenses	$29.32M	$33.47M
YoY Change	-28.84%	-2.3%
Deferred Revenue	$21.59M	$20.50M
YoY Change	-30.18%	-21.85%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$67.93M	$74.92M
YoY Change	-23.49%	4.83%
LONG-TERM LIABILITIES
Long-Term Debt	$25.00M	$25.00M
YoY Change	0.0%	0.0%
Other Long-Term Liabilities	$67.00K	$76.00K
YoY Change	-74.81%	-76.83%
Total Long-Term Liabilities	$25.07M	$25.08M
YoY Change	-0.79%	-0.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$67.93M	$74.92M
Total Long-Term Liabilities	$25.07M	$25.08M
Total Liabilities	$210.7M	$221.2M
YoY Change	-6.19%	86.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$806.8M	-$765.2M
YoY Change	32.31%	39.13%
Common Stock	$859.0M	$855.0M
YoY Change	22.68%	24.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$52.20M	$89.80M
YoY Change
Total Liabilities & Shareholders Equity	$262.9M	$311.0M
YoY Change	-16.5%	23.24%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$41.70M	-$54.30M
YoY Change	-30.27%	4.02%
Depreciation, Depletion And Amortization	$430.0K	$324.0K
YoY Change	101.88%	42.73%
Cash From Operating Activities	-$46.08M	-$61.83M
YoY Change	-184.4%	38.1%
INVESTING ACTIVITIES
Capital Expenditures	$470.0K	$399.0K
YoY Change	-210.33%	-160.73%
Acquisitions
YoY Change
Other Investing Activities	$104.3M	-$5.040M
YoY Change	-748.93%	-94.39%
Cash From Investing Activities	$103.8M	-$5.439M
YoY Change	-729.31%	-93.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-150.0K	73.18M
YoY Change	-101.41%	80.57%
NET CHANGE
Cash From Operating Activities	-46.08M	-61.83M
Cash From Investing Activities	103.8M	-5.439M
Cash From Financing Activities	-150.0K	73.18M
Net Change In Cash	57.55M	5.907M
YoY Change	18.07%	-106.24%
FREE CASH FLOW
Cash From Operating Activities	-$46.08M	-$61.83M
Capital Expenditures	$470.0K	$399.0K
Free Cash Flow	-$46.55M	-$62.23M
YoY Change	-184.6%	41.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	67155000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	56034000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3219000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	291000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	1025000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	760000	usd
	us-gaap	Interest Expense InterestExpense	2008000	usd
	us-gaap	Interest Expense InterestExpense	1484000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2194000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-469000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-54307000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-52219000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-61000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-126000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54368000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52345000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-54307000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-54307000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-52219000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-52219000	usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115608156	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115608156	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111583765	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111583765	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	121741000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60462000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	96000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5485000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47258000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	39899000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	606000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5348000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-126000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-52219000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	134034000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	92057000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21795000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6407000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	164000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-56163000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	64294000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	71875000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-319000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-381000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1992000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-419000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3337000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4383000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9502000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4904000	usd
	mrsn	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	1344000	usd
	mrsn	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	1493000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1421000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1199000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-12956000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	33970000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90839000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52731000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4043000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	93620000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100361000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	427000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	963000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	606000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	131000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	142000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	94729000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100921000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-153000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42609000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129363000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178425000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	367000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	333000	usd
	mrsn	Equity Issuance Costs Incurred During Noncash Or Part Noncash Transaction EquityIssuanceCostsIncurredDuringNoncashOrPartNoncashTransaction	81000	usd
	mrsn	Equity Issuance Costs Incurred During Noncash Or Part Noncash Transaction EquityIssuanceCostsIncurredDuringNoncashOrPartNoncashTransaction	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	1637000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1100000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	298000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-54300000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-765200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, management’s judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk and Off-balance Sheet RiskFinancial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.
	mrsn	Contract With Customer Liability Increase ContractWithCustomerLiabilityIncrease	808000	usd
	mrsn	Contract With Customer Liability Decrease ContractWithCustomerLiabilityDecrease	13764000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	134697000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3944000	usd
	mrsn	Contract With Customer Liability Increase ContractWithCustomerLiabilityIncrease	40000000	usd
	mrsn	Contract With Customer Liability Decrease ContractWithCustomerLiabilityDecrease	6030000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	37914000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	8497000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4284000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	13607000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	21000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128885000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128732000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177947000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	135338000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129363000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129210000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178425000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135816000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	157905000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	66000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	157856000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	151980000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	31000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	184000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	151827000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	13	security
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	84200000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	security
	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q2	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	10741000	usd
CY2022Q4	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	14822000	usd
CY2023Q2	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	8378000	usd
CY2022Q4	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	11536000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7591000	usd
CY2023Q2	mrsn	Accrued Preclinical Expenses Current AccruedPreclinicalExpensesCurrent	4589000	usd
CY2022Q4	mrsn	Accrued Preclinical Expenses Current AccruedPreclinicalExpensesCurrent	2767000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1649000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1865000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	520000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	636000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33468000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	43184000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25000000	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25000000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	280000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	360000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	25080000	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013	mrsn	Class Of Warrant Or Right Securities Called By Warrants Or Rights Number Issued ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued	129491	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.05
CY2013	mrsn	Contractual Life Of Warrants ContractualLifeOfWarrants	P10Y
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	22590	shares
	mrsn	Warrants Exercised In Period WarrantsExercisedInPeriod	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16052928	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11944664	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16052928	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11944664	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10051283	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.84
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2864451	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.11
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	97596	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	458953	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	11.15
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12359185	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.97
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6591352	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.21
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.88
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.95
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	400000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12241188	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12241188	shares

Files In Submission

Name	View Source	Status
0001628280-23-027989-index-headers.html	Edgar Link	pending
0001628280-23-027989-index.html	Edgar Link	pending
0001628280-23-027989.txt	Edgar Link	pending
0001628280-23-027989-xbrl.zip	Edgar Link	pending
a101inducementrsu-april202.htm	Edgar Link	pending
a1022017planrsuagreement.htm	Edgar Link	pending
a103directorrsuagreement-a.htm	Edgar Link	pending
exhibit31110-qfy2023q2.htm	Edgar Link	pending
exhibit31210-qfy2023q2.htm	Edgar Link	pending
exhibit32110-qfy2023q2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrsn-20230630.htm	Edgar Link	pending
mrsn-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mrsn-20230630_cal.xml	Edgar Link	unprocessable
mrsn-20230630_def.xml	Edgar Link	unprocessable
mrsn-20230630_pre.xml	Edgar Link	unprocessable
mrsn-20230630_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mrsn-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

2023 Q3 Form 10-Q Financial Statement

#000162828023027989 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN Mersana Therapeutics, Inc. Stock $mrsn

2023 Q3 Form 10-Q Financial Statement

#000162828023027989 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn